|Videos|August 19, 2022
Second-Line Treatment Approaches for R/R DLBCL
Author(s)Ian Flinn, MD, PhD
An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.
Advertisement
Advertisement
Related Articles
- Blood Cancer Awareness Month: Advances in Lymphoma
September 16th 2025
- Blood Cancer Awareness Month: Unmet Needs in Lymphoma
September 16th 2025
- Treatment Decision and Conclusion
September 8th 2025
- Analyses of the NAPOLI-3 Trial
September 8th 2025
- Outpatient Epcoritamab Demonstrates Efficacy and Safety in R/R DLBCL
September 4th 2025
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Novel ADC Earns FDA Fast Track in Head and Neck Cancer
2
Improved Survival Observed in CABINET Trial of Pancreatic NETs
3
PALOMA-2 Results for First-Line Subcutaneous Amivantamab in NSCLC
4
Dato-DXd Shows Tolerability Vs Chemo in HER2- Metastatic Breast Cancer
5